Progressive multifocal leukoencephalopathy (PML) can rarely occur in Multiple Sclerosis (MS) patients undergoing dimethyl fumarate (DMF) treatment. Our case stresses the limits of current diagnostic and stratification risk criteria, highlighting the potential role of Magnetic Resonance Imaging (MRI) in advising clinical choices.
Possible progressive multifocal leukoencephalopathy and active multiple sclerosis under dimethyl fumarate: the central role of MRI in informing therapeutic decisions / Vola, Elena Augusta; Petracca, Maria; Cocozza, Sirio; De Angelis, Marcello; Carotenuto, Antonio; Pontillo, Giuseppe; Morra, Vincenzo Brescia; Tedeschi, Enrico; Lanzillo, Roberta. - In: BMC NEUROLOGY. - ISSN 1471-2377. - 21:1(2021), p. 146. [10.1186/s12883-021-02165-0]
Possible progressive multifocal leukoencephalopathy and active multiple sclerosis under dimethyl fumarate: the central role of MRI in informing therapeutic decisions
Vola, Elena Augusta;Petracca, Maria;Cocozza, Sirio;De Angelis, Marcello;Carotenuto, Antonio;Pontillo, Giuseppe;Morra, Vincenzo Brescia;Tedeschi, Enrico;Lanzillo, Roberta
2021
Abstract
Progressive multifocal leukoencephalopathy (PML) can rarely occur in Multiple Sclerosis (MS) patients undergoing dimethyl fumarate (DMF) treatment. Our case stresses the limits of current diagnostic and stratification risk criteria, highlighting the potential role of Magnetic Resonance Imaging (MRI) in advising clinical choices.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
